{"id":"2afebf73-898b-50fb-b08a-4c8a918c6ef7","stable_key":"6cdb37aa-8998-5ea8-829d-4f995caf98fc:l-carnitine-alc-neuropathy-null","predicate":"did_not_prevent","statement":"In a 409-patient randomized trial during adjuvant taxane chemotherapy, acetyl-L-carnitine did not significantly improve the primary 12-week neuropathy endpoint.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"60cc1a11-63ad-5fef-be88-76d576ec7301","mechanism_event_label":"A plausible nerve-protection idea failed its main clinical test.","subject":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"object":{"id":"d69d84d1-506e-5bc4-a03f-accb17c14662","slug":"human-taxane-neuropathy","display_name":"Human taxane-associated peripheral neuropathy severity","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"60cc1a11-63ad-5fef-be88-76d576ec7301","stable_key":"6cdb37aa-8998-5ea8-829d-4f995caf98fc:l-carnitine-alc-neuropathy-null-event","event_type":"observed_relationship","label":"A plausible nerve-protection idea failed its main clinical test.","description":"In a 409-patient randomized trial during adjuvant taxane chemotherapy, acetyl-L-carnitine did not significantly improve the primary 12-week neuropathy endpoint.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"d69d84d1-506e-5bc4-a03f-accb17c14662","slug":"human-taxane-neuropathy","display_name":"Human taxane-associated peripheral neuropathy severity","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"6e34c035-9371-578f-b799-fd2a14e9e40f","slug":"l-carnitine","display_name":"L-Carnitine","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Women with breast cancer; 3 g/day acetyl-L-carnitine versus placebo.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"A finding for this derivative and treatment context, not every carnitine use.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"L-Carnitine collection; isomer, preparation, species, exposure and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"l-carnitine","display_name":"L-Carnitine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"A plausible nerve-protection idea failed its main clinical test.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. · 2013 · https://pubmed.ncbi.nlm.nih.gov/23733756/ · DOI 10.1200/JCO.2012.44.8738","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"88b9686d-1cbc-532a-9d3f-1a3df73a11d7","evidence_kind":"source_excerpt","locator":"Lines 330-336","start_line":330,"end_line":336,"excerpt":"## l-carnitine-alc-neuropathy-null\nA plausible nerve-protection idea failed its main clinical test.\nIn a 409-patient randomized trial during adjuvant taxane chemotherapy, acetyl-L-carnitine did not significantly improve the primary 12-week neuropathy endpoint.\nModel: Women with breast cancer; 3 g/day acetyl-L-carnitine versus placebo.\nLimitations: A finding for this derivative and treatment context, not every carnitine use.\nEvidence access: Primary abstract\nRandomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. · 2013 · https://pubmed.ncbi.nlm.nih.gov/23733756/ · DOI 10.1200/JCO.2012.44.8738","model_system":"Women with breast cancer; 3 g/day acetyl-L-carnitine versus placebo.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"e2c9c42b-806a-55e2-abde-b0320ea94704","stable_key":"import-6cdb37aa-8998-5ea8-829d-4f995caf98fc","title":"L-Carnitine: synthesis, acyl-group transport, fuel selection and nutrient interactions (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"6fcd86d9d02babb48b2ce658d506afe84580ad4b242f93f11f742d934fa5b361","revision_id":"398e3b52-45bc-52e3-891e-656c19ca674f","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}